References
- United States Food and Drug Administration. https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapies-treat-patients-sickle-cell-disease
- European Medicines Agency. https://www.ema.europa.eu/en/medicines/human/EPAR/casgevy
- Bluebird Bio. https://investor.bluebirdbio.com/news-releases/news-release-details/bluebird-bio-announces-fda-approval-lyfgeniatm-lovotibeglogene
- Fierce Pharma. Bluebird signs major coverage deal for sickle cell gene therapy Lyfgenia, easing some price concerns. https://www.fiercepharma.com/pharma/bluebird-signs-first-deal-sickle-cell-gene-therapy-lyfgenia-covering-nearly-third-us
- United States Food and Drug Administration. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-pirtobrutinib-chronic-lymphocytic-leukemia-and-small-lymphocytic
- Lilly. https://investor.lilly.com/news-releases/news-release-details/jaypircar-pirtobrutinib-now-approved-us-fda-treatment-adult
- Astra Zeneca. https://www.astrazeneca.com/media-centre/press-releases/2023/wainua-eplontersen-granted-first-ever-regulatory-approval-us-treatment-of-adults-with-polyneuropathy-hereditary-transthyretin-mediated-amyloidosis.html
- Coelho T, Marques W Jr, Dasgupta NR et al. NEURO-TTRansform Investigators. Eplontersen for hereditary transthyretin amyloidosis with polyneuropathy. JAMA 2023;330(15):1448–1458. doi: 10.1001/jama.2023.18688
- Chiesi. https://chiesirarediseases.com/media/fda-approval-for-filsuvez-topical-gel
- European Medicines Agency. https://www.ema.europa.eu/en/medicines/human/EPAR/filsuvez
- Novartis. https://www.novartis.com/news/media-releases/novartis-receives-fda-approval-fabhalta-iptacopan-offering-superior-hemoglobin-improvement-absence-transfusions-first-oral-monotherapy-adults-pnh
- Risitano AM, Röth A, Soret J et al. Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal hemoglobinuria and active hemolysis: an open-label, single-arm, Phase II, proof-of-concept trial. Lancet Haematol. 2021;8(5):e344–e354. doi: 10.1016/S2352-3026(21)00028-4
- Jang JH, Wong L, Ko BS et al. Iptacopan monotherapy in patients with paroxysmal nocturnal hemoglobinuria: a 2-cohort open-label proof-of-concept study. Blood Adv. 2022;6(15):4450–4460. doi: 10.1182/bloodadvances.2022006960
- Novartis. https://www.novartis.com/news/media-releases/novartis-investigational-iptacopan-phase-iii-study-demonstrates-clinically-meaningful-and-statistically-significant-proteinuria-reduction-patients-c3-glomerulopathy-c3g
- European Medicines Agency. https://www.ema.europa.eu/en/medicines/human/EPAR/loargys#ema-inpage-item-authorization-details
- Immedica. https://www.immedica.com/en/press/loargysr-pegzilarginase-approved-eu-treatment-arginase-1-deficiency-arg1-d-2185053
- Astellas. https://www.astellas.com/en/news/28761
- European Medicines Agency. https://www.ema.europa.eu/en/medicines/human/EPAR/veoza
- Lederman S, Ottery FD, Cano A et al. Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study. Lancet. 2023;401(10382):1091–1102. doi: 10.1016/S0140-6736(23)00085-5
- Johnson KA, Martin N, Nappi RE et al. Efficacy and Safety of Fezolinetant in Moderate to Severe Vasomotor Symptoms Associated With Menopause: A Phase 3 RCT. J Clin Endocrinol Metab 2023; 108(8):1981–1997. doi: 10.1210/clinem/dgad058
- Neal-Perry G, Cano A, Lederman S et al. Safety of Fezolinetant for Vasomotor Symptoms Associated With Menopause. A Randomized Controlled Trial. Obstet Gynecol. 2023;41(4):737–747. doi: 10.1097/AOG.0000000000005114
- United States Food and Drug Administration. https://www.fda.gov/news-events/press-announcements/fda-approves-novel-drug-treat-moderate-severe-hot-flashes-caused-menopause
- Biogen. https://investors.biogen.com/news-releases/news-release-details/chmp-issues-positive-opinion-biogens-skyclarysr-omaveloxolone
- European Medicines Agency. https://www.ema.europa.eu/en/medicines/human/EPAR/skyclarys
- Lee A. Omaveloxolone: first approval. Drugs 2023;83(8):725–729. doi: 10.1007/s40265-023-01874-9
- Biogen. https://investors.biogen.com/news-releases/news-release-details/biogen-completes-acquisition-reata-pharmaceuticals
- European Medicines Agency. https://www.ema.europa.eu/en/medicines/human/EPAR/pomalidomide-viatris
- European Medicines Agency. https://www.ema.europa.eu/en/medicines/human/EPAR/imnovid-previously-pomalidomide-celgene
- European Medicines Agency. https://www.ema.europa.eu/en/medicines/human/EPAR/velsipity
- Pfizer. https://www.pfizer.com/news/press-release/press-release-detail/us-fda-approves-pfizers-velsipitytm-adults-moderately
- Merck. https://www.merck.com/news/merck-and-eisai-provide-update-on-two-phase-3-trials-evaluating-keytruda-pembrolizumab-plus-lenvima-lenvatinib-in-patients-with-certain-types-of-metastatic-non-small-cell-lung-cancer/
- Merck. https://www.merck.com/news/moderna-and-merck-announce-mrna-4157-v940-in-combination-with-keytruda-pembrolizumab-demonstrated-continued-improvement-in-recurrence-free-survival-and-distant-metastasis-free-survival-in-pa/
- Carvalho T. Personalized anti-cancer vaccine combining mRNA and immunotherapy tested in melanoma trial. Nat Med 2023;29(10):2379–2380. doi: 10.1038/d41591-023-00072-0
- Lilly. https://investor.lilly.com/news-releases/news-release-details/zepboundtm-tirzepatide-now-available-us-pharmacies-adults-living
- Lilly. https://lilly.mediaroom.com/2023-12-11-Lillys-Zepbound-TM-tirzepatide-achieved-additional-6-7-weight-loss-following-a-36-week-open-label-lead-in-period,-for-a-total-mean-weight-loss-of-26-0-from-study-entry-over-88-weeks
- Aronne LJ, Sattar N, Horn DB et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA 2024; 331(1):38–48. doi: 10.1001/jama.2023.24945
- Alkermes. https://investor.alkermes.com/news-releases/news-release-details/alkermes-plc-announces-agreement-sell-athlone-ireland-facility
- Fierce Pharma Novo Nordisk submits application for massive manufacturing campus near Dublin. https://www.fiercepharma.com/manufacturing/novo-nordisk-submits-application-massive-manufacturing-campus-near-dublin
- Lilly. https://investor.lilly.com/news-releases/news-release-details/lilly-completes-acquisition-point-biopharma
- POINT Biopharma. https://www.pointbiopharma.com/our-products/pipeline/prostate-cancer